Biogen (BUE:BIIB) Effect of Exchange Rate Changes : ARS-9,561 Mil (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Biogen Effect of Exchange Rate Changes?

Biogen's Effect of Exchange Rate Changes for the three months ended in Mar. 2025 was ARS36,565 Mil.

Biogen's Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 was ARS-9,561 Mil.

Biogen Effect of Exchange Rate Changes Historical Data

The historical data trend for Biogen's Effect of Exchange Rate Changes can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Effect of Exchange Rate Changes Chart

Biogen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Effect of Exchange Rate Changes

Get a 7-Day Free Trial

5,615.22

-6,039.20

-9,338.11

12,671.10

-68,377.00

Biogen Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Effect of Exchange Rate Changes	Get a 7-Day Free Trial															-19,461.75	-11,283.30	40,301.20	-75,144.00	36,565.07

Biogen Effect of Exchange Rate Changes Calculation

Effect of Exchange Rate Changes represents the effect of exchange rate changes on cash balances held in foreign currencies.

Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-9,561 Mil.

Biogen Effect of Exchange Rate Changes Related Terms

Thank you for viewing the detailed overview of Biogen's Effect of Exchange Rate Changes provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Effect of Exchange Rate Changes

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy 0R1B:UK IDP:Germany BIIB:Chile BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.